| This week's sponsor is FierceBiotech. | |  | |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. While the names in 2018’s top 15 pharma companies have stayed the same, the order has shifted: Sanofi has slipped two places to No. 7, as its sales sank almost 2% year over year, while Gilead—famously under hepatitis C pricing pressure for years—fell even further, down three spots to No. 13. On the flip side, Bristol-Myers Squibb climbed from 15th to 12th and may leap ahead even higher next year, should it complete its Celgene buyout and add an extra $15 billion or so in annual sales. 2019 should also see a new entrant in Takeda, which recently scooped up Shire but didn’t release its combined 2018 financials in time to be eligible for these rankings. | |
|
Featured Story | | | Monday, April 8, 2019 The big names always turn up near the top of yearly sales rankings, and this year is no different. Many companies on this list have faced big patent losses in recent years, while some have big launches coming up, too. |
|
|
Top Stories Of The Week Monday, April 8, 2019 Novartis CEO Vas Narasimhan is ready to shell out $10 billion a year on acquisitions as he looks to build on deals he's already made. One example? Gene therapy, as the company's $8.7 billion AveXis acquisition is about to pay off with a widely expected FDA approval. Thursday, April 4, 2019 Amgen and Novartis have seen high demand for their migraine prevention drug Aimovig, but that's not stopping Amgen from wanting to exit their collaboration. Monday, April 8, 2019 Over the past year, Sanofi and Alnylam have been retooling their 2014 R&D pact around Alnylam's RNA tech; today, the pair signaled its end, and former Sanofi partner Regeneron has stepped in. Sunday, April 7, 2019 Allergan's rapastinel, the centerpiece of its $560 million acquisition of Naurex, recently failed in pivotal trials in depression. But scientists at Duke University and Villanova University may have found another use for the drug: to aid in opioid withdrawal. Friday, April 5, 2019 Amid the recalls plaguing the "sartan" drug class, the FDA released a list of 40 generics that do not contain three potentially carcinogenic compounds linked to various "sartan" drugs, including valsartan and losartan. Tuesday, April 9, 2019 Rare disease biotech Cyclerion has poached Shire’s ex-head of R&D, Andy Busch, Ph.D., as its new chief innovation officer, less than 18 months after he joined the company from his long stint at Bayer. Friday, April 5, 2019 Amazon has announced that its smartspeaker voice assistant Alexa is now HIPAA-compliant and can serve as your very own healthcare valet. To start, the retail and computing giant has paired up with six companies to develop programs that can harbor protected prescription information, book doctor appointments, track blood glucose levels and find the nearest urgent care center. Monday, April 8, 2019 In a back-and-forth final matchup, Boehringer Ingelheim’s ad campaign for Ofev pulled away from GlaxoSmithKline’s Trelegy to land the #FierceMadness ad tournament crown. Monday, April 8, 2019 Injecting a vaccine directly into tumor sites produced remissions in mice and in a small number of lymphoma patients in a study at Mount Sinai. The results were so promising a clinical trial has opened that will test the technique in lymphoma and two other cancers. Tuesday, April 9, 2019 When Aurobindo forked over $1 billion to snap up some of Novartis’ unwanted drugs last year, it set the Indian drugmaker up to be the second-largest generics player in the U.S. But it is one that brings a history of quality issues when it comes to manufacturing, as exemplified in the latest thrashing by the FDA. Resources Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
|
